SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Pankaj Puri, Anil C. Anand, Vivek A. Saraswat, Subrat K. Acharya, Shiv K. Sarin, Radha K. Dhiman, Rakesh Aggarwal, Shivaram P. Singh, Deepak Amarapurkar, Anil Arora, Mohinish Chhabra, Kamal Chetri, Gourdas Choudhuri, Vinod K. Dixit, Ajay Duseja, Ajay K. Jain, Dharmesh Kapoor, Premashis Kar, Abraham Koshy, Ashish Kumar, Kaushal Madan, Sri P. Misra, Mohan V.G. Prasad, Aabha Nagral, Amarendra S. Puri, R. Jeyamani, Sanjiv Saigal, Samir Shah, Praveen K. Sharma, Ajit Sood, Sandeep Thareja, Manav Wadhawan, Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India, Journal of Clinical and Experimental Hepatology, 2014, 4, 2, 117

    CrossRef

  2. 2
    H. Ochi, D. Miki, C. N. Hayes, H. Abe, Y. Hayashida, M. Kubo, K. Chayama, IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population, Journal of General Virology, 2014, 95, Pt_6, 1297

    CrossRef

  3. 3
    Emmanuel A Tsochatzis, Jaime Bosch, Andrew K Burroughs, Liver cirrhosis, The Lancet, 2014, 383, 9930, 1749

    CrossRef

  4. 4
    A He, Lopa Mishra, Liver Metabolism and Fatty Liver Disease, 2014,

    CrossRef

  5. 5
    Giacomo Germani, Emmanuel Tsochatzis, Vasilios Papastergiou, Andrew K Burroughs, HCV in liver transplantation, Seminars in Immunopathology, 2013, 35, 1, 101

    CrossRef

  6. 6
    Samir A.H. Gheit, Marcel W. Keddeas, Eslam Safwat, Rapid virological response as a predictor of a sustained virological response in Egyptian patients with chronic hepatitis C genotype 4, Egyptian Liver Journal, 2013, 3, 1, 10

    CrossRef

  7. 7
    Muhammad Imran, Sobia Manzoor, Javed Ashraf, Madiha Khalid, Muqddas Tariq, Hafiza Khaliq, Sikandar Azam, Role of viral and host factors in interferon based therapy of hepatitis C virus infection, Virology Journal, 2013, 10, 1, 299

    CrossRef

  8. 8
    Yeon Joo Kim, Sung Bum Cho, Sang Woo Park, Hyoung Ju Hong, Du Hyeon Lee, Eun Ae Cho, HyunSoo Kim, Sung Kyu Choi, Jong Sun Rew, Body Mass Index and Nonresponse to Antiviral Treatment in Korean Patients with Genotype 2 and 3 Chronic Hepatitis C, Chonnam Medical Journal, 2012, 48, 1, 21

    CrossRef

  9. 9
    Won Gil Chung, Hong Joo Kim, Young Gil Choe, Hyo Sun Seok, Chang Wook Chon, Yong Kyun Cho, Byung Ik Kim, Young Yool Koh, Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection, Clinical and Molecular Hepatology, 2012, 18, 2, 195

    CrossRef

  10. You have free access to this content10
    Emmanuel A. Tsochatzis, Jaime Bosch, Andrew K. Burroughs, New therapeutic paradigm for patients with cirrhosis, Hepatology, 2012, 56, 5
  11. 11
    Margaret F. Bassendine, David A. Sheridan, Daniel J. Felmlee, Simon H. Bridge, Geoffrey L Toms, R. Dermot G. Neely, HCV and the hepatic lipid pathway as a potential treatment target, Journal of Hepatology, 2011, 55, 6, 1428

    CrossRef

  12. 12
    Kate Frazer, Michele Glacken, Barbara Coughlan, Anthony Staines, Leslie Daly, Hepatitis C virus infection in primary care: survey of registered nurses’ knowledge and access to information, Journal of Advanced Nursing, 2011, 67, 2
  13. 13
    Paul J. Clark, Alexander J. V. Thompson, Andrew J. Muir, IL28B Polymorphisms and Treatment of Hepatitis C, Current Hepatitis Reports, 2011, 10, 1, 70

    CrossRef

  14. 14
    Elisabetta Cariani, Rosina Critelli, Cristina Rota, Monica Luongo, Tommaso Trenti, Erica Villa, Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C, Journal of Virological Methods, 2011, 178, 1-2, 235

    CrossRef

  15. 15
    Luigi E Adinolfi, Luciano Restivo, Rosa Zampino, Amedeo Lonardo, Paola Loria, Metabolic alterations and chronic hepatitis C: treatment strategies, Expert Opinion on Pharmacotherapy, 2011, 12, 14, 2215

    CrossRef

  16. 16
    Elisabetta Cariani, Erica Villa, Cristina Rota, Rosina Critelli, Tommaso Trenti, Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection, Clinical Chemistry and Laboratory Medicine, 2011, 49, 8

    CrossRef

  17. 17
    Masayuki Kurosaki, Kotaro Matsunaga, Itsuko Hirayama, Tomohiro Tanaka, Mitsuaki Sato, Yutaka Yasui, Nobuharu Tamaki, Takanori Hosokawa, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Hiroki Ikeda, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Megumu Higaki, Nobuyuki Enomoto, Namiki Izumi, A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis, Hepatology Research, 2010, 40, 3
  18. 18
    Kazuaki Chayama, C. Nelson Hayes, Kentaro Yoshioka, Hisataka Moriwaki, Takeshi Okanoue, Shotaro Sakisaka, Tetsuo Takehara, Makoto Oketani, Joji Toyota, Namiki Izumi, Yoichi Hiasa, Akihiro Matsumoto, Hideyuki Nomura, Masataka Seike, Yoshiyuki Ueno, Hiroshi Yotsuyanagi, Hiromitsu Kumada, Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C, Hepatology Research, 2010, 40, 12
  19. 19
    T.J.S. Cross, A. Quaglia, J. Nolan, S. Hughes, P.M. Harrison, Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?, Journal of Medical Virology, 2010, 82, 6
  20. 20
    A.A. Pillai, V.S. Lee, E. Wang, M.E. Rinella, J. Levitsky, Factors Associated With Sustained Virological Response in Liver Transplant Recipients With Recurrent Hepatitis C, Transplantation Proceedings, 2010, 42, 9, 3647

    CrossRef

  21. 21
    J Michael Estep, Zobair M Younossi, Hepatitis C and metabolic syndrome, Expert Review of Endocrinology & Metabolism, 2010, 5, 2, 209

    CrossRef

  22. 22
    Aymin Delgado-Borrego, David Healey, Betania Negre, Marielle Christofi, Sabina Sabharwal, David A Ludwig, Raymond T Chung, Maureen M Jonas, Influence of Body Mass Index on Outcome of Pediatric Chronic Hepatitis C Virus Infection, Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 2, 191

    CrossRef

  23. 23
    François Bailly, Si Nafa Si Ahmed, Pierre Pradat, Christian Trepo, Management of nonresponsive hepatitis C, Expert Review of Anti-infective Therapy, 2010, 8, 4, 379

    CrossRef

  24. 24
    Reetta Huttunen, Jaana Syrjänen, Obesity and the outcome of infection, The Lancet Infectious Diseases, 2010, 10, 7, 442

    CrossRef

  25. 25
    J. Madill, B. Arendt, E. Aghdassi, C. Chow, M. Guindi, G. Therapondos, L. Lilly, J. Allard, Oxidative Stress and Nutritional Factors in Hepatitis C Virus–Positive Liver Recipients, Controls, and Hepatitis C Virus–Positive Nontransplant Patients, Transplantation Proceedings, 2010, 42, 5, 1744

    CrossRef

  26. 26
    M. Isabel Fiel, Pathology of Chronic Hepatitis B and Chronic Hepatitis C, Clinics in Liver Disease, 2010, 14, 4, 555

    CrossRef

  27. 27
    Namiki Izumi, Yasuhiro Asahina, Masayuki Kurosaki, Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors, Hepatitis Research and Treatment, 2010, 2010, 1

    CrossRef

  28. 28
    F. Morisco, T. Stroffolini, E. Medda, D. C. Amoruso, P. L. Almasio, E. Villa, M. Zuin, B. Paris, M. Stanzione, N. Caporaso, Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study, Journal of Viral Hepatitis, 2010, 17, 6
  29. 29
    Christophe Moreno, Pierre Deltenre, Jean-Michel Pawlotsky, Jean Henrion, Michael Adler, Philippe Mathurin, Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis, Journal of Hepatology, 2010, 52, 1, 25

    CrossRef

  30. 30
    Toshihiko Mizuta, Yasunori Kawaguchi, Yuichiro Eguchi, Hirokazu Takahashi, Keisuke Ario, Takumi Akiyama, Noriko Oza, Taiga Otsuka, Takuya Kuwashiro, Toru Yoshimura, Akitaka Hisatomi, Iwata Ozaki, Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral Load, Digestive Diseases and Sciences, 2010, 55, 1, 183

    CrossRef

  31. 31
    JULES L. DIENSTAG, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  32. 32
    Hesham M. Elgouhari, Claudia O. Zein, Ibrahim Hanouneh, Ariel E. Feldstein, Nizar N. Zein, Diabetes Mellitus Is Associated with Impaired Response to Antiviral Therapy in Chronic Hepatitis C Infection, Digestive Diseases and Sciences, 2009, 54, 12, 2699

    CrossRef

  33. 33
    Marshall B. Elam, George S. Cowan, Robert J. Rooney, M. Lloyd Hiler, Chandrahasa R. Yellaturu, Xiong Deng, George E. Howell, Edwards A. Park, Ivan C. Gerling, Divyan Patel, J. Christopher Corton, Lauren M. Cagen, Henry G. Wilcox, Malay Gandhi, Micheal H. Bahr, Micheal C. Allan, Linus A. Wodi, George A. Cook, Thomas A. Hughes, Rajendra Raghow, Hepatic Gene Expression in Morbidly Obese Women: Implications for Disease Susceptibility, Obesity, 2009, 17, 8
  34. 34
    F. Negro, S. Clément, Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C, Journal of Viral Hepatitis, 2009, 16, 10
  35. 35
    Nicolás Merchante, Ignacio de los Santos-Gil, Dolores Merino, Mercedes González-Serrano, José A. Mira, Jesús Sanz-Sanz, Elisa Fernández-Fuertes, Josefa Ruiz-Morales, José del Valle, Juan Macías, Antonio Moro, Juan A. Pineda, Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients, Journal of Hepatology, 2009, 50, 4, 684

    CrossRef

  36. 36
    Cristian Vallejos, Talya Bordin-Wosk, Lara Pockros, Anne Feng, Paul Pockros, Narcotic Analgesics and Progression of Fibrosis in Patients With Chronic Hepatitis C, Journal of Clinical Gastroenterology, 2009, 43, 4, 357

    CrossRef

  37. 37
    T. J. S. Cross, A. Quaglia, S. Hughes, D. Joshi, P. M. Harrison, The impact of hepatic steatosis on the natural history of chronic hepatitis C infection, Journal of Viral Hepatitis, 2009, 16, 7
  38. 38
    Paolo Caraceni, Marco Domenicali, Ferdinando Giannone, Mauro Bernardi, The role of the endocannabinoid system in liver diseases, Best Practice & Research Clinical Endocrinology & Metabolism, 2009, 23, 1, 65

    CrossRef

  39. 39
    Krisztina Hagymási, János Fehér, A testsúlycsökkentés hatása a kombinált interferon-alfa-2a + ribavirin kezelésre adott válaszra idült HCV-hepatitisben, Orvosi Hetilap, 2008, 149, 46, 2189

    CrossRef

  40. 40
    P. Couzigou, P. Mathurin, L. Serfaty, P. Cacoub, J. Moussalli, G. Pialoux, P. Chossegros, L. Cattan, S. Pol, Alcool, stéatohépatite métabolique, insulinorésistance et hépatite C, Gastroentérologie Clinique et Biologique, 2008, 32, 3, S74

    CrossRef

  41. 41
    Michael Economou, Haralampos Milionis, Spyridon Filis, Gerasimos Baltayiannis, Leonidas Christou, Moses Elisaf, Epameinondas Tsianos, Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2008, 23, 4
  42. 42
    Zhisheng Liu, Weidong Ma, Huikai Li, Qiang Li, Clinicopathological and prognostic features of primary clear cell carcinoma of the liver, Hepatology Research, 2008, 38, 3
  43. 43
    Shinichi Harada, Ayaka Nawa, Wakako Hamabe, SungHi Kim, Yoko Akimoto, Mao Shikata, Noriyo Kimura, Satoko Izawa, Aya Ohtani, Noriko Sasase, Kouichirou Ohyama, Masayoshi Motoshima, Midori Hirai, Teruko Hirooka, Shizuka Nabeshima, Kazuhiko Tanaka, KeIh Kim, SooRyang Kim, Shogo Tokuyama, Efficacy of Pegylated Interferon and Ribavirin Combination Therapy in Chronic Hepatitis C and Influence of Lipid Factors, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2008, 34, 4, 355

    CrossRef

  44. 44
    A. Schneider, M. Momma, Folgeerkrankungen und Komplikationen der Adipositas, Der Gastroenterologe, 2008, 3, 5, 391

    CrossRef

  45. 45
    Hesham M. Elgouhari, Hari S. Conjeevaram, Impact of obesity, hepatic steatosis, and insulin resistance on hepatitis C treatment outcomes, Current Hepatitis Reports, 2008, 7, 3, 127

    CrossRef

  46. 46
    Nila Rafiq, Zobair M Younossi, Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C, Expert Review of Gastroenterology & Hepatology, 2008, 2, 2, 207

    CrossRef

  47. 47
    Sumio Watanabe, Reiko Yaginuma, Kenichi Ikejima, Akihisa Miyazaki, Liver diseases and metabolic syndrome, Journal of Gastroenterology, 2008, 43, 7, 509

    CrossRef

  48. 48
    Joji Toyota, Yosiyasu Karino, Jun Akaike, Takumi Ohmura, Takahiro Sato, Katu Yamazaki, Yasuaki Kuwata, Tomohiro Arakawa, Shigeyuki Furuya, Kazuhiro Matuyama, Takao Harada, Prediction of efficacy and viral kinetics using COBAS TaqMan HCV "automated" during antiviral treatment of hepatitis C, Kanzo, 2008, 49, 7, 297

    CrossRef

  49. 49
    J. J. BLONSKY, S. A. HARRISON, Review article: nonalcoholic fatty liver disease and hepatitis C virus – partners in crime, Alimentary Pharmacology & Therapeutics, 2008, 27, 10
  50. 50
    Dominique Guyader, Comment traiter les malades non répondeurs à la bithérapie antivirale C ?, Gastroentérologie Clinique et Biologique, 2007, 31, 3, 317

    CrossRef

  51. 51
    Hideyuki Nomura, Yoichiro Kashiwagi, Ryouko Hirano, Hironori Tanimoto, Nobuo Tsutsumi, Masashi Higashi, Hiromi Ishibashi, Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study, Hepatology Research, 2007, 37, 7
  52. 52
    Einar Björnsson, Paul Angulo, Hepatitis C and Steatosis, Archives of Medical Research, 2007, 38, 6, 621

    CrossRef

  53. 53
    Dawn M. Torres, Stephen A. Harrison, Hepatitis C, insulin resistance, and steatosis, Current Hepatitis Reports, 2007, 6, 4, 129

    CrossRef

  54. 54
    M. Trauner, Klinische Bedeutung – Sinn und Unsinn – der Leberbiopsie bei NAFLD, Der Diabetologe, 2007, 3, 3, 192

    CrossRef

  55. 55
    Cristina Tural, Ramon Planas, Guillermo Sirera, Bonaventura Clotet, Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers, Current Opinion in HIV and AIDS, 2007, 2, 6, 496

    CrossRef

  56. 56
    Nyingi Kemmer, Guy W. Neff, Managing chronic hepatitis C in the difficult-to-treat patient, Liver International, 2007, 27, 10
  57. 57
    Pierre M. Gholam, Angela F. Domingo, Mechanisms of glucose intolerance in patients with chronic hepatitis C: Implications for treatment, Current Infectious Disease Reports, 2007, 9, 2, 110

    CrossRef

  58. You have free access to this content58
    Shivakumar Chitturi, Geoffrey C Farrell, Etsuko Hashimoto, Toshiji Saibara, George KK Lau, José D Sollano, Non-alcoholic fatty liver disease in the Asia–Pacific region: Definitions and overview of proposed guidelines, Journal of Gastroenterology and Hepatology, 2007, 22, 6
  59. 59
    Robert F. Kushner, Obesity Management, Gastroenterology Clinics of North America, 2007, 36, 1, 191

    CrossRef

  60. 60
    Rami Moucari, Patrick Marcellin, Tarik Asselah, Stéatose au cours de l’hépatite chronique C : rôle de l’insulino-résistance et des facteurs viraux, Gastroentérologie Clinique et Biologique, 2007, 31, 8-9, 643

    CrossRef

  61. 61
    Sam Galhenage, Manal F. Abdelmalek, The impact of steatosis and alcohol on hepatitis C, Current Hepatitis Reports, 2007, 6, 2, 39

    CrossRef

  62. 62
    Gökhan S. Hotamisligil, Inflammation and metabolic disorders, Nature, 2006, 444, 7121, 860

    CrossRef

  63. 63
    Stephen H. Caldwell, Curtis K. Argo, Abdullah M. S. Al-Osaimi, Nonalcoholic Fatty Liver Disease,